Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy
62% of patients were progression-free at 18 months post-transplantation
Will cancer vaccine boost immunotherapy’s efficacy?
Immune checkpoint inhibitor and oncolytic viral immunotherapy produce synergistic effect
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Enroll patients now in KEYNOTE-630 trial
Another option for immunotherapy